SynthesisZeitschrift fur Rheumatologie2017
Meta-analysis of circulating adiponectin, leptin, and resistin levels in systemic sclerosis.
Synthesis in Zeitschrift fur Rheumatologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications.Archives of dermatological research · 2021Trial
- In the Pursuit of Metabolic Markers of Systemic Sclerosis-Plasma Adiponectin and Omentin-1 in Monitoring the Course of the Disease.International journal of molecular sciences · 2023Article
- Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review.International journal of molecular sciences · 2023Review
- Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis.Frontiers in immunology · 2023Article
- Adiponectin Deregulation in Systemic Autoimmune Rheumatic Diseases.International journal of molecular sciences · 2021Review
- Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies.Frontiers in medicine · 2021Review
- The role of leptin in selected skin diseases.Lipids in health and disease · 2020Review
- Role of adipokines in systemic sclerosis pathogenesis.European journal of rheumatology · 2020Review
- Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis.Archives of dermatological research · 2020Article
- The Role of Adipose Tissue in the Pathogenesis and Therapeutic Outcomes of Inflammatory Bowel Disease.Cells · 2019Review
- Clinical associations of serum leptin and leptin/adiponectin ratio in systemic sclerosis.Postepy dermatologii i alergologii · 2019Article
- The role of adipokines in systemic sclerosis: a missing link?Archives of dermatological research · 2019Review
- Interfacial Adipose Tissue in Systemic Sclerosis.Current rheumatology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to evaluate the relationship between circulating blood adipokine levels and systemic sclerosis (SSc).
methodsWe conducted a meta-analysis on serum/plasma adiponectin, leptin, or resistin levels in patients with SSc and controls, and performed a subgroup analysis based on ethnicity and/or disease type.
resultsEleven studies (511 patients with SSc and 341 controls) were included in the meta-analysis. Meta-analysis revealed that adiponectin levels were significantly lower in patients with SSc than in controls (standardized mean differences [SMD] = -0.638; 95 % confidence intervals [CI] = -1.154, -0.122; P = 0.015). Stratification by ethnicity showed a low adiponectin level associated with SSc in Caucasians (SMD = -0.439; 95 % CI = -1.092, -0.213; P = 0.187) and Asians (SMD = -1.006; 95 % CI = -2.031, -0.019; P = 0.055), although this result was not statistically significant. Stratification by disease type revealed that the adiponectin level was significantly lower in the diffuse SSc, but not limited SSc, group than in the control (diffuse: SMD = -1.445; 95 % CI = -2.276, -0.614; P = 0.001; limited: SMD = 0.188; 95 % CI = -0.064, 0.439; P = 0.144). Meta-analysis showed no association between leptin levels and SSc (SMD = -0.029; 95 % CI = -1.362, 1.304; P = 0.966), and no association between resistin levels and SSc (SMD = 0.202; 95 % CI = -0.091, 0.496; P = 0.177).
conclusionsOur meta-analysis revealed a significantly lower circulating adiponectin level in patients with SSc than in controls. This difference was apparent in the diffuse type of SSc, but not in the limited type. However, circulating leptin and resistin levels were not different between patients with SSc and healthy controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.